The guinea pig as a preclinical model for demonstrating the efficacy and safety of statins

Journal of Pharmacology and Experimental Therapeutics

Volumn 324, Issue 2, 2008, Pages 576-586

  Madsen, Cort S ^a   Janovitz, Evan ^a   Zhang, Rongan ^a   Nguyen Tran, Van ^b   Ryan, Carol S ^a   Yin, Xiaohong ^a   Monshizadegan, Hossain ^a   Chang, Ming ^a   D'Arienzo, Celia ^a   Scheer, Susan ^a   Setters, Robert ^c   Search, Debra ^a   Chen, Xing ^a   Zhuang, Shaobin ^a   Kunselman, Lori ^a   Peters, Andrew ^a   Harrity, Thomas ^a   Apedo, Atsu ^a   Huang, Christine ^a   Cuff, Carolyn A ^d   Kowala, Mark C ^e   Blanar, Michael A ^a   Sun, Chong Qing ^a   Robl, Jeffrey A ^a   Stein, Philip D ^a,f   more..

^a BRISTOL MYERS SQUIBB   (United States)

^b GENOMICS INSTITUTE OF THE NOVARTIS RESEARCH FOUNDATION   (United States)

^c Palatin Technologies   (United States)

^d ABBOTT LABORATORIES   (United States)

^e ELI LILLY AND COMPANY   (United States)

^f Redpoint Bio Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

[ 7 [4 (4 FLUOROPHENYL) 6,7 DIHYDRO 2 (1 METHYLETHYL) 5H BENZO [6,7] CYCLOHEPTA [1,2 B]PYRIDIN 3 YL] 3,5 DIHYDROXY HEPTENOIC ACID) SODIUM SALT]; ATORVASTATIN; BMS 423526; CERIVASTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN; PRAVASTATIN; ROSUVASTATIN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CHOLESTEROL BLOOD LEVEL; CHOLESTEROL SYNTHESIS; CONTROLLED STUDY; DRUG ACTIVITY; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG POTENCY; DRUG RESPONSE; DRUG SAFETY; DRUG STRUCTURE; ENZYME ASSAY; GUINEA PIG; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HYPERCHOLESTEROLEMIA; IC 50; IN VITRO STUDY; IN VIVO STUDY; LIPOPHILICITY; LIQUID CHROMATOGRAPHY; LIVER MICROSOME; MALE; MYOPATHY; NONHUMAN; PRIORITY JOURNAL; RAT;

ANIMALS; CELLS, CULTURED; DRUG EVALUATION, PRECLINICAL; GUINEA PIGS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MALE; MODELS, ANIMAL; MUSCLE, SKELETAL; RATS; RATS, SPRAGUE-DAWLEY;

EID: 38749122430     PISSN: 00223565     EISSN: 15210103     Source Type: Journal    
DOI: 10.1124/jpet.107.131615     Document Type: Article

References (39)

1. Aktas M, Auguste D, Lefebvre HP, Toutain PL, and Braun JP (1993) Creatine kinase in the dog: a review. Vet Res Commun 17:353-369.
2. Arora R, Liebo M, and Maldonado F (2006) Statin-induced myopathy: the two faces of Janus. J Cardiovasc Pharmacol Ther 11:105-112.
3. Beg ZH, Stonik JA, and Brewer HB Jr (1977) Purification and characterization of 3-hydroxy-3-methylglutaryl coenzyme A reductase from chicken liver. FEBS Lett 80:123-129.
4. Berry MN and Friend DS (1969) High-yield preparation of isolated rat liver parenchymal cells: a biochemical and fine structural study. J Cell Biol 43:506-520.
5. Black AE, Hayes RN, Roth BD, Woo P, and Woolf TF (1999) Metabolism and excretion of atorvastatin in rats and dogs. Drug Metab Dispos 27:916-923.
6. Bligh EG and Dyer WJ (1959) A rapid method of total lipid extraction and purification. Can J Biochem Physiol 37:911-917.
7. Capuzzi DM and Margolis S (1971) Metabolic studies in isolated rat liver cells. I. Lipid synthesis. Lipids 6:601-608.
8. Conde K, Pineda G, Newton RS, and Fernandez ML (1999) Hypocholesterolemic effects of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors in the guinea pig: atorvastatin versus simvastatin. Biochem Pharmacol 58:1209-1219.
9. Cziraky MJ, Willey VJ, McKenney JM, Kamat SA, Fisher MD, Guyton JR, Jacobson TA, and Davidson MH (2006) Statin safety: an assessment using an administrative claims database. Am J Cardiol 97:61C-68C.
10. Davidson MH (2002) Rosuvastatin: a highly efficacious statin for the treatment of dyslipidaemia. Expert Opin Investig Drugs 11:125-141.
11. Fernandez ML and Volek JS (2006) Guinea pigs: a suitable animal model to study lipoprotein metabolism, atherosclerosis and inflammation. Nutr Metab (Lond) 3:17.
12. Grundy SM, Cleeman JI, Merz CN, Brewer HB, Jr., Clark LT, Hunninghake DB, Pasternak RC, Smith SC Jr, and Stone NJ (2004) Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation 110:227-239.
13. Hamilton-Craig I (2001) Statin-associated myopathy. Med J Aust 175:486-489.
14. Henck JW, Craft WR, Black A, Colgin J, and Anderson JA (1998) Pre- and postnatal toxicity of the HMG-CoA reductase inhibitor atorvastatin in rats. Toxicol Sci 41:88-99.
15. Horsmans Y, Desager JP, and Harvengt C (1990) Biochemical changes and morphological alterations of the liver in guinea-pigs after administration of simvastatin (HMG CoA reductase-inhibitor). Pharmacol Toxicol 67:336-339.
16. Ishigami M, Honda T, Takasaki W, Ikeda T, Komai T, Ito K, and Sugiyama Y (2001) A comparison of the effects of 3-hydroxy-3-methylglutaryl-coenzyme a (HMG-CoA) reductase inhibitors on the CYP3A4-dependent oxidation of mexazolam in vitro. Drug Metab Dispos 29:282-288.
17. Istvan ES and Deisenhofer J (2001) Structural mechanism for statin inhibition of HMG-CoA reductase. Science 292:1160-1164.
18. Jacobson TA (2006) Statin safety: lessons from new drug applications for marketed statins. Am J Cardiol 97:44C-51C.
19. Kantola T, Kivisto KT, and Neuvonen PJ (1998) Effect of itraconazole on the pharmacokinetics of atorvastatin. Clin Pharmacol Ther 64:58-65.
20. Krause BR and Newton RS (1995) Lipid-lowering activity of atorvastatin and lovastatin in rodent species: triglyceride-lowering in rats correlates with efficacy in LDL animal models. Atherosclerosis 117:237-244.
21. Kreisberg RA and Oberman A (2002) Clinical review 141: lipids and atherosclerosis: lessons learned from randomized controlled trials of lipid lowering and other relevant studies. J Clin Endocrinol Metab 87:423-437.
22. Laaksonen R (2006) On the mechanisms of statin-induced myopathy. Clin Pharmacol Ther 79:529-531.
23. Langer T and Levy RI (1968) Acute muscular syndrome associated with administration of clofibrate. N Engl J Med 279:856-858.
24. Lins RL, Matthys KE, Verpooten GA, Peeters PC, Dratwa M, Stolear JC, and Lameire NH (2003) Pharmacokinetics of atorvastatin and its metabolites after single and multiple dosing in hypercholesterolaemic haemodialysis patients. Nephrol Dial Transplant 18:967-976.
25. McKenney JM (2005) Pharmacologic options for aggressive low-density lipoprotein cholesterol lowering: benefits versus risks. Am J Cardiol 96:60E-66E.
26. McTaggart F, Buckett L, Davidson R, Holdgate G, McCormick A, Schneck D, Smith G and Warwick M (2001) Preclinical and clinical pharmacology of rosuvastatin, a new 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor. Am J Cardiol 87:28B-32B.
27. Nezasa K, Higaki K, Takeuchi M, Nakano M, and Koike M (2003) Uptake of rosuvastatin by isolated rat hepatocytes: comparison with pravastatin. Xenobiotica 33:379-388.
28. Omar MA, Wilson JP, and Cox TS (2001) Rhabdomyolysis and HMG-CoA reductase inhibitors. Ann Pharmacother 35:1096-1107.
29. Pasternak RC, Smith SC Jr, Bairey-Merz CN, Grundy SM, Cleeman JI, and Lenfant C (2002) ACC/AHA/NHLBI Clinical Advisory on the Use and Safety of Statins. Circulation 106:1024-1028.
30. Phillips PS, Haas RH, Bannykh S, Hathaway S, Gray NL, Kimura BJ, Vladutiu GD, and England JD (2002) Statin-associated myopathy with normal creatine kinase levels. Ann Intern Med 137:581-585.
31. Reijneveld JC, Koot RW, Bredman JJ, Joles JA, and Bar PR (1996) Differential effects of 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors on the development of myopathy in young rats. Pediatr Res 39:1028-1035.
32. Robl JA (2003) inventors; Bristol-Myers Squibb Co., assignee. HMG-CoA reductase inhibitors and method. U.S. Patent 6,620,821 B2. 2003 Sept 16.
33. Schachter M (2005) Chemical, pharmacokinetic and pharmacodynamic properties of statins: an update. Fundam Clin Pharmacol 19:117-125.
34. Suzuki H, Aoki T, Tamaki T, Sato F, Kitahara M, and Saito Y (1999) Hypolipidemic effect of NK-104, a potent HMG-CoA reductase inhibitor, in guinea pigs. Atherosclerosis 146:259-270.
35. Thompson PD, Clarkson PM, and Rosenson RS (2006) An assessment of statin safety by muscle experts. Am J Cardiol 97:69C-76C.
36. Walsh KM, Albassam MA, and Clarke DE (1996) Subchronic toxicity of atorvastatin, a hydroxymethylglutaryl-coenzyme A reductase inhibitor, in beagle dogs. Toxicol Pathol 24:468-476.
37. Westwood FR, Bigley A, Randall K, Marsden AM, and Scott RC (2005) Statin-induced muscle necrosis in the rat: distribution, development, and fibre selectivity. Toxicol Pathol 33:246-257.
38. Wierzbicki AS (2001) Atorvastatin. Expert Opin Pharmacother 2:819-830.
39. Wooltorton E (2001) Bayer pulls cerivastatin (Baycol) from market. CMAJ 165:632.